our Technology & Innovations
Cutting-edge technologies, pioneered by our own scientific team.
Plant Extraction
113 Botanicals extraction technology is characterised as follows
Low pressure and low temperature
Lower energy and running costs
Produces extracts that closely replicate the plant in composition of bioactive molecules
Full spectrum extract and no isolation or re-blending is required
Selective: waxes and high molecular weight polyphenols are not co-extracted
No down-stream purification steps are necessary
Sphericann ™ Capsule Technology
Polymeric matrix technology designed to deliver a controlled, sustained-release ingested formulation
The elimination of gastric acids hydrolysis of the actives content of the formulation means that lower dose sizes are needed
A more direct, non pulmonary, route of administration to the systemic circulation with the aim to improve dosing regime and management
Offers an alternative to vaping/inhalation and sublingual methods
Measured dose sizes with the aim to give more precise dose management to both patient and prescribing clinician
Transdermal delivery
113 Botanicals, in collaboration with the University of Sussex, are developing a transdermal delivery method with a focus on optimising dose management, rate of delivery and bioavailability. Its aim: to offer a further additional innovative route of administration for patient groups for whom other delivery methods are unsuitable, undesirable or physically inaccessible.
Transdermal delivery of cannabinoids has the potential to offer a number of advantages such as:
Bypass of the hepatic first pass effect.
Zero-order release kinetics, leading to controlled drug delivery with steady plasma/drug concentration.
Controlled dose management
A readily acceptable delivery format: suitable for patient groups for whom vaping/inhalation and/or oral ingestion may be unsuitable or undesirable.